Fibrinogen Concentrate, Human (FCH) + Cryoprecipitate
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Afibrinogenemia
Conditions
Afibrinogenemia, Hypofibrinogenemia, Fibrinogen Deficiency
Trial Timeline
Oct 1, 2009 → Mar 1, 2014
NCT ID
NCT00916656About Fibrinogen Concentrate, Human (FCH) + Cryoprecipitate
Fibrinogen Concentrate, Human (FCH) + Cryoprecipitate is a phase 3 stage product being developed by CSL for Afibrinogenemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00916656. Target conditions include Afibrinogenemia, Hypofibrinogenemia, Fibrinogen Deficiency.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00916656 | Phase 3 | Withdrawn |
Competing Products
3 competing products in Afibrinogenemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BT524 (Part I) + BT524 (Part II) | ICON plc. | Phase 3 | 74 |
| FIB Grifols | Grifols | Phase 3 | 74 |
| Human Plasma-Derived Fibrinogen Concentrate | Grifols | Phase 1/2 | 38 |